JPS6485072A - Recombinant vaccinia virus - Google Patents
Recombinant vaccinia virusInfo
- Publication number
- JPS6485072A JPS6485072A JP62240514A JP24051487A JPS6485072A JP S6485072 A JPS6485072 A JP S6485072A JP 62240514 A JP62240514 A JP 62240514A JP 24051487 A JP24051487 A JP 24051487A JP S6485072 A JPS6485072 A JP S6485072A
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- originated
- recombinant
- recombinant vector
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700618 Vaccinia virus Species 0.000 title abstract 5
- 108020004414 DNA Proteins 0.000 abstract 3
- 101710149951 Protein Tat Proteins 0.000 abstract 3
- 239000002299 complementary DNA Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 210000001691 amnion Anatomy 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000006801 homologous recombination Effects 0.000 abstract 1
- 238000002744 homologous recombination Methods 0.000 abstract 1
- 208000033065 inborn errors of immunity Diseases 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
PURPOSE:To produce tat protein in high expressivity, by using a cDNA coding tat protein originated from human immunodeficiency syndrome virus HIV and synthesizing a recombinant vaccinia virus by integrating said cDNA in a specific region. CONSTITUTION:The 1st recombinant vector is prepared by integrating a DNA region nonessential to the proliferation of vaccinia virus. A region coding tat protein originated from HIV is inserted to the downstream of the promoter of the 1st recombinant vector to obtain the 2nd recombinant vector. The 2nd recombinant vector is introduced into a cultural cell of an animal infected with vaccinia virus to induce a homologous recombination between the vector DNA and the virus genom DNA to construct the objective recombinant vaccinia virus. The cultured animal cell is e.g. TK-143 originated from human osteosarcoma and FL originated from human amnion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62240514A JPS6485072A (en) | 1987-09-25 | 1987-09-25 | Recombinant vaccinia virus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62240514A JPS6485072A (en) | 1987-09-25 | 1987-09-25 | Recombinant vaccinia virus |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6485072A true JPS6485072A (en) | 1989-03-30 |
Family
ID=17060653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62240514A Pending JPS6485072A (en) | 1987-09-25 | 1987-09-25 | Recombinant vaccinia virus |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6485072A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012137071A2 (en) | 2011-04-06 | 2012-10-11 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
-
1987
- 1987-09-25 JP JP62240514A patent/JPS6485072A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012137071A2 (en) | 2011-04-06 | 2012-10-11 | Biovaxim Limited | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3853422D1 (en) | HIV-3 retrovirus and its use. | |
CA2107732A1 (en) | Retrovirus from the hiv group and its use | |
EP0278940A3 (en) | Hepatitis b virus surface antigens and hybrid antigens containing them | |
CA2104396A1 (en) | Viral particles having altered host range | |
NZ269019A (en) | Method of inducing transduction with retroviral assistance | |
MY117686A (en) | Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof | |
DK1224314T3 (en) | Lentiviral triplex DNA, as well as vectors and recombinant cells, contain lentiviral triplex DNA | |
EP0265785A3 (en) | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells | |
JPS6479124A (en) | Factor viii analogue, manufacture and medicine | |
NO921969L (en) | NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | |
EP1001032A3 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
ES8105388A1 (en) | DNA transfer vector, host transformed with it, vaccine, and their production. | |
MY103182A (en) | Vaccines against acquired immune deficiency syndrome. | |
IL86650A0 (en) | Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane | |
JPS6446651A (en) | Antibody for retrovirus polypeptide | |
EA200000528A1 (en) | METHOD FOR OBTAINING VACCINES TO PREVENT PATHOGENIC EFFECTS ASSOCIATED WITH RETROVIRAL INFECTION | |
RU2003128991A (en) | RECOMBINANT POXVIRUS CODING HIMERA IMMUNODEFICIENCY VIRUS CHEMICAL PROTEINS | |
CA2169603A1 (en) | Retrovirus from the hiv group and its use | |
WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
Hejdeman et al. | DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy | |
JPS6485072A (en) | Recombinant vaccinia virus | |
ES2061850T3 (en) | RECOMBINANT VIRUSES OF MAREK'S DISEASE, ITS PREPARATION PROCEDURE AND VACCINE. | |
EP0327180A3 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
AU2190288A (en) | Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained | |
WO2001042299A3 (en) | Hepatitis virus sentinel virus i (svi) |